Cancer Treatment - Introduction
HYDROS, Inc. was formed in 1996 in Los Angeles, California for the funding, development and marketing in North America of the deuterium depleted water products developed by HYD Ltd.
HYD Ltd. is a Hungarian company established in 1993 to develop pharmaceutical and consumer products that utilize a novel proprietary procedure for treatment of various types of cancer and other proliferative/neoplastic diseases, utilizing submolecular medicine. This novel procedure uses deuterium depletion as a method for slowing down, halting and reversing the growth of cancer cells.
HYDROS, Inc. is in the process of obtaining FDA approval for the marketing of the new therapeutic modality using deuterium depleted water in fighting cancer. For the current status, see the latest news release.
The Invention has been tested in preclinical animal studies and patented in several countries. Phase II Clinical Trials were closed August 2000. The patient information
was compiled and the final evaluations, results and benefits confirmed the same positive results as reported in the
previous Intermediate Evaluation Report.
See the Summary of Intermediate Evaluation.
In 2003, we began marketing our "Nutritional
Supplement" product, "Preventa-105 Deuterium Depleted Carbonated
Drinking Water".
